Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: Shell R. Poust who wrote (9296)	12/26/1998 1:06:00 AM
From: virgil vancleave	Respond to of 14162

I think that the FDA wanted more info and more test data on one of their drugs which delayed approval in the us. The product is approved overseas and company is profitable, has cash of over 2 per share and is buying stock back (up to 10 percent of outstanding shares). While the october delay was a letdown, it may well be a nice buying opportunity long term and even a good covered call candidate at that. add to the fundamentals company has no outstanding debt and won't need to do equity offerings to raise money. Also, a few more potential large drugs in the pipeline. I am still long, luckily only 300 at 11; but am considering buying more at 5 or below. I will try to post more info and charts if anyone is interested. I have to work tomorrow, so it would be on sunday evening. just my opinion. good luck